Verapamil ( DrugBank: Verapamil )
3 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
96 | クローン病 | 1 |
140 | ドラベ症候群 | 1 |
167 | マルファン症候群 | 2 |
96. クローン病
臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01261286 (ClinicalTrials.gov) | August 2010 | 14/12/2010 | Drug-Disease Interaction in Crohn's Disease | Pharmacodynamics and Pharmacokinetics of Verapamil in Crohn's Disease Patients | Crohn's Disease | Drug: verapamil | University of Alberta | NULL | Completed | 18 Years | 65 Years | Both | Phase 1 | Canada |
140. ドラベ症候群
臨床試験数 : 104 / 薬物数 : 61 - (DrugBank : 14) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 63
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01607073 (ClinicalTrials.gov) | April 2012 | 24/5/2012 | Verapamil as Therapy for Children and Young Adults With Dravet Syndrome | Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome | Dravet Syndrome | Drug: Verapamil | Gillette Children's Specialty Healthcare | Mayo Clinic;Ann & Robert H Lurie Children's Hospital of Chicago;Dartmouth-Hitchcock Medical Center | Completed | 2 Years | 25 Years | All | 2 | Phase 2 | United States |
167. マルファン症候群
臨床試験数 : 20 / 薬物数 : 39 - (DrugBank : 10) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01295047 (ClinicalTrials.gov) | July 2006 | 11/2/2011 | Comparison of Medical Therapies in Marfan Syndrome. | Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial | Marfan Syndrome | Drug: Atenolol;Drug: VERAPAMIL;Drug: Perindopril | Cardiff University | NULL | Completed | 16 Years | 60 Years | Both | 18 | Phase 4 | United Kingdom |
2 | EUCTR2005-000749-13-GB (EUCTR) | 30/07/2005 | 20/06/2005 | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | Marfan Syndrome | Trade Name: Atenolol Product Name: Atenolol Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A Trade Name: Coversyl Product Name: Coversyl Product Code: N/A INN or Proposed INN: N/A Other descriptive name: PERINDOPRIL Trade Name: Verapamil Product Name: Verapamil SR Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A | Cardiff University | NULL | Not Recruiting | Female: yes Male: yes | 60 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |